ACT Brief: Bayesian Shifts Regulatory Culture, Quality Tolerance Limits Drive Risk Management, CBER Leadership Changes

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In the final segment of his video interview, David Morton, PhD, director of biostatistics at Certara, discussed how FDA guidance is encouraging adaptive, data-driven trial designs. Early engagement on priors and external controls fosters collaboration, moving away from rigid designs toward probabilistic decision-making, with a hybrid ecosystem emerging where Bayesian approaches become standard in appropriate contexts.
• An analysis of quality tolerance limits across nearly 580 trials reveals practical implementation patterns for risk-based quality management. With 39% of studies exceeding tolerance thresholds and breaches often occurring in specific windows, quick triage and documented decisions proved effective, with median breach duration of two snapshots allowing rapid restoration of compliance.
• Vinay Prasad is stepping down as head of the FDA's Center for Biologics Evaluation and Research, returning to UCSF after implementing major reforms including the two-to-one pivotal trial requirement and a risk-stratified framework for ultra-rare diseases. His tenure saw record approvals but also controversial decisions, reflecting ongoing tension between accelerating pathways and maintaining trial rigor.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.